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Abstract
Background Digital interventions (DIs) are increasingly being used in mental health care, despite limited evidence regarding 
their value for money. This study aimed to evaluate the cost effectiveness of DIs for generalised anxiety disorder (GAD), in 
comparison with alternative care options, from the perspective of the UK health care system.
Methods An open-source decision analytic cohort model was used to extrapolate the results of a network meta-analysis 
over a patient’s lifetime and estimate the costs and outcomes (quality-adjusted life-years) of DIs and their comparators. The 
net monetary benefit (NMB) and probability of cost effectiveness was estimated for each comparator, and we conducted a 
Value of Information analysis to evaluate the scale and drivers of uncertainty.
Results DIs were associated with lower NMB compared with medication and with group therapy, but greater NMB com-
pared with non-therapeutic controls and with usual care. DIs that were supported by a clinician, an assistant or a lay person 
had higher delivery costs than purely patient-self-directed DIs, yielding a greater NMB when opportunity cost was above 
£3000/QALY. There was considerable uncertainty in the findings driven largely by uncertainty in the estimated treatment 
effects. The value of further research to establish the effectiveness of DIs for GAD was substantial, at least £12.9 billion.
Conclusions The high uncertainty about these results does not allow for recommendations based on the cost effectiveness 
of DIs. However, the analysis highlights areas for future research, and demonstrates that apparent cost savings associated 
with DIs can be offset by reduced effectiveness.
1  Background
Digital interventions (DIs) use software programmes 
accessed via computers, smartphones, audio-visual equip-
ment and other devices to deliver therapeutic activities that 
aim to prevent and improve health problems. DIs lend them-
selves well to mental health care, where they have been used 
as alternatives or as add-ons to conventional therapies to 
improve access, patient choice and clinical outcomes. In 
England, National Health Service (NHS) investment in DIs 
is growing [1]. Such investment can be large and irrevers-
ible (e.g. through investment in training and infrastructure 
to deliver such interventions), so we need to understand the 
circumstances in which DIs offer value for money relative 
to alternative care options.
Generalised anxiety disorder (GAD) is a noteworthy con-
dition for which DIs might be used to improve outcomes. It is 
the most common mental health problem in terms of weekly 
prevalence, but it is often misunderstood for other conditions 
(especially depression or panic) when self-reported, or it is 
mixed with other common mental disorders in research trials 
and evidence syntheses [2]. GAD can be magnified at times 
of crisis as it is defined by stress and worry about day-to-
day life and struggling to tolerate uncertainty [3]; it is also 
associated with significant physical symptoms that lead to 
high health care and medical costs [4].
Compared with depression, evidence about the costs and 
outcomes of DIs specific to GAD populations is limited. 
Previous studies that evaluated the cost effectiveness of DIs 
with GAD populations [5, 6] compared a specific DI with 
usual care or individual therapy. To our knowledge, there are 
no studies that have synthesised the available evidence on 
all DIs for GAD in order to evaluate their cost effectiveness 
across different technologies and therapeutic modalities. 
Reviews of cost effectiveness of DIs were for mixed mood 
and anxiety disorders, so they were dominated by DIs for 
depression and did not report outcomes for GAD popula-
tions separately [7, 8].
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This study aims to evaluate the cost effectiveness of DIs, 
across different technologies and therapeutic modalities, in 
comparison with (a) conventional therapy (without any digi-
tal components), (b) medication, (c) non-therapeutic con-
trols and (d) usual care, from the perspective of the UK’s 
health care system.
2  Methods
2.1  Classification of Digital Interventions (DIs) 
and Their Alternatives
To pool and compare different types of DIs and their controls 
for GAD, a systematic literature review and network meta-anal-
ysis [9] was conducted in which DIs and their alternatives were 
classified according to three criteria: (a) whether they were a 
psychological/behavioural intervention or a non-therapeutic 
psychological/behavioural control; (b) whether they were digi-
tal or non-digital; and (c) whether they were supported.
‘Digital’ infers a software-based platform bespoke to the 
delivery of a specific activity. ‘Controls’ could be a psycho-
logical placebo (e.g. ‘sham’ activity), an attention control (e.g. 
non-therapeutic interaction with a researcher), or a change in 
usual care due to research processes (e.g. regular monitoring 
to ensure retention to follow-up). ‘Supported’ interventions/
controls were defined by having a two-way interaction between 
the patient and another person (clinician or lay person).
Waiting lists and usual care were classified under usual 
care unless an active component (e.g. monitoring, sham 
activity) was introduced, in which case the waiting list/usual 
care was classified as non-therapeutic control. An additional 
classification group was included for pharmacological inter-
ventions (i.e. medication).
In total, we included seven comparators based on our 
classification criteria: medication, where selective serotonin 
reuptake inhibitors (SSRIs) were the only pharmacotherapy 
identified in the review that has been directly compared with 
digital interventions for GAD; face-to-face group therapy, 
the only supported non-digital intervention identified in the 
review; supported digital intervention (SDI); unsupported 
digital intervention (UDI); supported digital control (SDC); 
unsupported digital control (UDC); usual care. There were 
no available clinical studies that compared digital interven-
tions with unsupported non-digital interventions or unsup-
ported non-digital controls, and no studies with supported 
non-digital controls that used GAD-7 as an outcome. Details 
of the digital interventions and controls are provided in Sup-
plementary File 1 of the Electronic Supplementary Mate-
rial (ESM). It is possible that the taxonomy did not account 
for all differences between interventions within each group. 
Alternative, more granular classification was explored in the 
network meta-analysis [9], and is discussed in further detail 
in Sect. 4, under limitations.
2.2  Analytical Perspective
Analysis was conducted from the NHS and Personal Social 
Services perspective. A full incremental analysis was under-
taken comparing all seven interventions/controls simultane-
ously over a patient’s lifetime. The cost-effectiveness analy-
sis methods followed the National Institute for Health and 
Care Excellence (NICE) reference case [10]. We included 
costs associated with health care use and intervention 
delivery, as incurred by the health system. Outcomes were 
measured in terms of quality-adjusted life-years (QALYs) 
that capture the length and the health-related quality of life 
(HRQoL).
2.3  Model Structure
The model structure (Fig. 1) was based on previously pub-
lished models, namely those by Kumar et al. [5], adapted to 
be used with the available data on outcomes in this study. 
The model was validated by clinical researchers on the team 
(LG) and advisors to the project. In the model, patients’ 
outcomes were derived from GAD severity determined 
by the Generalised Anxiety Disorder-7 item questionnaire 
(GAD-7), whose scores denoted no anxiety (scores 0–4), 
mild (5–9), moderate (10–14) or severe (15–21) anxiety 
[11]. Each health state (GAD severity level) was associated 
with a corresponding health care cost, HRQoL and mortal-
ity, driven by GAD and associated comorbidities.
At the start of the model, patients were in one of three 
health states: mild, moderate or severe anxiety. At each sub-
sequent cycle of the model (every 3 months over patients’ 
lifetime), they could remain in this health state or transition 
to a better or worse health state, including no GAD. The 
distribution of patients across the health states was derived 
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from the distribution of the expected GAD-7 score at each 
time point. As patients passed through states they accrued 
costs and QALYs. The effect of DIs is to reduce the severity 
of GAD, therefore reduce the probability of being in mod-
erate and severe GAD states, with an associated impact on 
costs and QALYs. Patient were 46.7 years old and female 
on entering the model; the patient population was based on 
the population used to inform state-specific utilities in the 
model where 72.4% of the population was female [12]. The 
model was implemented in RStudio, version 1.3.1093 [13], 
the code is available in the online supplementary files (see 
ESM).
2.4  Model Parameters
2.4.1  Intervention Effectiveness
Changes in GAD-7 scores, as a result of the seven com-
parators, were informed by a network meta-analysis of 
DIs for patients diagnosed with GAD [9]. The meta-anal-
ysis reported GAD-7 scores after treatment (3–12 weeks), 
adjusted by baseline scores. GAD-7 scores were modelled as 
a continuous variable; scores generated in the meta-analysis 
model that fell between severity states (e.g. a GAD-7 score 
of 9.5), were rounded up.
Baseline GAD-7 scores were used to determine the pro-
portion of patients in the three health states (mild, mod-
erate, severe GAD). Post-treatment (cycle 2) patients can 
transition to another state, including no GAD and death, or 
remain in their existing state. Changes in GAD severity in 
the remaining cycles were estimated based on evidence from 
the literature. Without treatment, patients’ GAD symptoms 
were assumed to improve over time, as reported by Yonkers 
et al. [14]. Specifically, 15% of patients recovered in the 
first year, a further 10% in the second year, and a further 
5% in the third year. In the model, recovery was defined as 
a move from mild, moderate or severe anxiety to the next 
(lower) anxiety state. In the base case, the treatment effect 
was assumed to remain constant indefinitely, implying that, 
while patients’ GAD symptoms may change over time, 
the proportion of patients in each health state, on average, 
would not change. The cost of any additional treatment was 
assumed to be captured in health care costs. Alternative, 
more conservative assumptions were explored in sensitivity 
analysis (Sect. 2.5.2). In addition, in the base case, patients 
on treatment were assumed to improve over time at the same 
rate as those who hadn’t received treatment.
2.4.2  State‑Specific Utilities and Costs
Targeted searches were conducted to inform state-specific 
health care costs and utilities in no, mild, moderate and 
severe anxiety. Details of the search strategies and results 
are provided in Supplementary File 2 (see ESM).
In the base case, the utilities were informed by Revicki 
et al. [12], a study conducted in 297 adult patients with GAD 
recruited from an integrated care setting in the US (72%, 
mean age 47.69 years). In the study, GAD severity states 
were defined by the Hamilton Anxiety Scale (HAM-A) [15] 
score, an assessment tool highly correlated with the GAD-7 
questionnaire (r = 0.852 [16]). Utilities were elicited using 
an SF-12 Health Survey (SF-6D).
The HRQoL/utility scores associated with the GAD-7 
states were assumed to follow an underlying age deprecia-
tion over time, according to UK population utility score 
norms (per year of age) [17].
State-specific health care costs were informed by a UK-
based study [18], adjusted to 2019 GBP using the overall 
Consumer Price Index [19, 20].
Costs and benefits were discounted at 3.5% over the time 
horizon of the model [10, 21].
2.4.3  Mortality
Age- and sex-dependent mortality risk in patients with no 
anxiety was obtained from the Office for National Statistics 
[22]. Excess mortality in mild, moderate and severe anxiety 
states was derived from Michal et al. [23], who reported all-
cause excess mortality in patients with mild, moderate and 
severe anxiety or depression, defined by PHQ-4 scores. All 
excess mortality was assumed to be caused by GAD, captur-
ing deaths due to suicide and GAD-related co-morbidities. 
The reported risk ratios were applied to all-cause mortality.
2.4.4  Intervention Cost
Intervention costs were derived from published literature. 
The cost of usual care was assumed to depend on GAD 
severity and was captured in state-specific health care costs 
(Sect. 2.4.2). The cost of pharmacotherapy was assumed 
to represent the cost of medication (£16.42 representing 
Fig. 1  Model structure
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the mean cost of all SSRIs [24] weighted by the volume 
dispensed in January 2020 [25]), the dispensing fees (12 
prescriptions dispensed annually at £1.26 each [24]), and 
GP appointments (7.5 in the first year of treatment and 4 
thereafter for a further 4 years, as per NICE guidance for 
prescribing [26], at £42.60 each). On advice from clinical 
researchers on the project, medication was assumed to be 
prescribed for 5 years as a conservative estimate to prevent 
underestimating its cost. The duration was chosen because 
antidepressant medication in treatment-naïve patients may 
be given for up to 2 years, but relapse is common within the 
first year after of stopping the medication, which may lead 
to another 2 years of prescription.
The cost of face-to-face group therapy was based on the 
time spent with a therapist, multiplied by the cost of the ther-
apist’s time (£53 per hour [27]). The group sizes were 5–9, 
lasting 9–10.5 h [28, 29]. The intervention was thus costed 
at 1.5 h of therapist time per patient (10.5 h/7 patients).
A recent review of economic evaluations of digital mental 
health interventions [30] found that the methods for cost-
ing these interventions varied greatly between studies. In 
this study, the cost of the digital component of interven-
tions/controls and their maintenance was assumed to be 
zero in the base case, assuming that, if the intervention is 
rolled out nationally, the marginal cost per patient would 
be negligible. Alternative costs were explored in scenario 
analyses (Sect. 2.5.2). Unsupported digital interventions and 
controls (UDCs and UDIs) were assumed to incur no addi-
tional human resource costs for their delivery. The human 
resource cost of SDIs and SDCs was calculated separately, 
based on the level of support (e.g. who provided the support, 
for how long, and how often) typically required to deliver 
them, detailed in supplementary file 3 (see ESM).
2.5  Cost‑Effectiveness Analysis
Cumulative costs and QALYs over a lifetime were used to 
derive the net monetary benefit (NMB) for each compara-
tor, using Eq. (1). Increasing NMB implies better value for 
money.
where k is the opportunity cost of the health system [31].
NMB is the preferred method for comparing cost effec-
tiveness of multiple treatment options [32]; it represents 
the difference between the benefit incurred by an interven-
tion and its opportunity cost [33]. In our base case, k was 
£15,000/QALY, comparable to the empirical estimate of 
the opportunity cost in the UK [34], but alternative values 
(£0/QALY to £30,000/QALY) were explored in sensitivity 
analysis.
(1)NMB = QALY × k − cost
2.6  Sensitivity Analysis
2.6.1  Probabilistic Analysis
Probabilistic analysis was conducted to characterise the 
uncertainty associated with model parameters, and deter-
mine their impact on cost effectiveness. Each parameter was 
sampled 25,000 times from its probability distribution to 
match the number of iterations output from the NMA that 
directly informed intervention effectiveness in the economic 
model. The model parameters and their probability distribu-
tions are shown in Table 1 and Supplementary File 4 (see 
ESM).
2.6.2  Deterministic Scenario Analysis
One-way scenario analysis was performed to evaluate the 
sensitivity of the model results to our assumptions. The fol-
lowing scenarios were explored regarding the GAD trajec-
tory, health care resource use and intervention costs:
Five additional scenarios regarding the GAD trajectory, 
assuming different rates of diminishing treatment effect 
and assuming no spontaneous improvement. Specifically, 
the treatment effect was assumed to remain constant for 
1 year, then either diminish immediately or diminish 
gradually for 10 years before returning to pre-treatment 
GAD-7 scores. The scenarios were chosen based on clini-
cal opinion (see Supplementary File 5 in the ESM for 
further detail).
Two alternative scenarios regarding health care resource 
use, where state-specific health care costs were informed 
using alternative studies: Vera-Llonch et al. [35] and 
Kumar et al. [5] (see Supplementary File 6 in the ESM 
for details).
Alternative costs of digital interventions, where a thresh-
old analysis was performed to identify the maximum cost 
of DIs that would make them good value for money.
Alternative level of support in supported digital con-
trols—5 minutes per patient, delivered by non-clinical 
staff (£1.50) or by clinical psychologists (£3.00).
2.7  Value of Information Analysis
The results from probabilistic sensitivity analysis were 
used to conduct value of information (VOI) analysis, on a 
population level. Estimated population-level value of perfect 
information  (EVPIP) represents the difference between the 
NMB derived from perfect information (where the optimum 
treatment is known with certainty) and existing information 
(i.e. the expected net benefit from the treatment that is the 
most cost effective under the current state of knowledge) 
Digital Interventions for GAD
[36]. Intuitively, it is interpreted as the maximum amount 
that should be spent on research to resolve model uncer-
tainty, given the potential impact, or benefit, of the research 
findings. To derive  EVPIP, the incidence of GAD in Eng-
land was assumed to be 250,000 people per annum (assum-
ing incidence is 4.9% per annum [37], and 10% of patients 
receive the intervention), and the lifetime of the interven-
tion was conservatively estimated to be 5 years. Methods 
are described in further detail in Supplementary File 7 (see 
ESM).
The estimated value of perfect parameter information 
at population level  (EVPPIP) was derived to identify the 
parameters in the model that drove uncertainty relevant 
to the adoption decision.  EVPPIP represents the maxi-
mum amount that should be spent on research to resolve 
uncertainty around an individual parameter (or group of 
parameters), given the potential impact, or benefit, of the 
research findings.  EVPPIP was derived using the non-par-
ametric method developed by Strong et al. [38], using the 
SAVI interface (http:// savi. shef. ac. uk/ SAVI/).  EVPPIP was 
Table 1  Model parameters, with measures of uncertainty
CI confidence interval, ESM electronic supplementary material, GAD-7 generalised anxiety disorder 7 score, RR relative risk, SDC supervised 
digital controls, SDI supervised digital interventions, SSRIs selective serotonin reuptake inhibitors, UDC unsupervised digital controls, UDI 
unsupervised digital interventions
*Uncertainty in utilities was derived by fitting a beta distribution to the reported mean and standard error, using the method of moments [4]
**Beta distribution applied to the risk of death in each state, then 25,000 random samples used to derive the relative risk
Parameter Mean Probability distribution Source
Baseline GAD-7 score 10.68 ~ N (10.68, 1.83) Saramago Goncalves 
et al. submitted [9]
GAD-7 score after treatment Saramago Goncalves 
et al. submitted [9] UDC 8.77 ~ N (8.77, 3.72)
 SDC 8.76 ~ N (8.76, 3.14)
 UDI 8.01 ~ N (8.01, 3.16)
 SDI 7.22 ~ N (7.22, 1.82)
 Group therapy 6.51 ~ N (6.51, 3.59)
 SSRIs 4.08 ~ N (4.08, 1.89)
Interventions cost
 Usual care, UDC, UDI £0 Assumed
 SDC £18 Derived
 SDI £80 Derived
 Group therapy £80 Derived
 SSRIs (per year) £351.04 in year 1, £201.94 thereafter Derived
Health care cost Gamma (shape, scale) Kaltenthaler et al. [18]
 No anxiety 86 (1.960, 0.016)
 Mild anxiety 200 (0.848, 0.003)
 Moderate anxiety 210 (0.295, 0.001)
 Severe anxiety 324 (0.320, 0.0007)
 Dead 0
Utilities Mean (SD) used to derive 
beta parameters*
Revicki et al. [12]
 No anxiety 0.72 0.72 (0.10)
 Mild anxiety 0.64 0.64 (0.10)
 Moderate anxiety 0.60 0.60 (0.10)
 Severe anxiety 0.53 0.60 (0.10)
 Dead 0
Age-related utility decrements Age specific, see Table S3.3 in ESM
Mortality—general population Sex, and age specific, see Table S3.3 in ESM
Excess mortality (RR) Non-parametric CI** Michal et al. [23]
 Mild anxiety 1.20 (0.82–1.67)
 Moderate anxiety 1.58 (1.06–2.24)
 Severe anxiety 2.17 (1.47–3.05)
 D. Jankovic et al.
derived for five groups of parameters: treatment effect (post-
treatment GAD-7 scores, seven parameters); state-specific 
health care costs (four parameters); state-specific utilities 
(four parameters); excess death (three parameters—relative 
risk of death in mild, moderate and severe anxiety), age-
related utility decrements (54 parameters, utility decrements 
every year until all patients in the model die). For methods, 
see Supplementary File 7 in the ESM.
3  Results
3.1  Generalised Anxiety Disorder Trajectory
Figure 2 shows the proportion of patients in each health state 
for the initial 5 years, with usual care. At the start of the model, 
the majority of patients had mild or moderate GAD (17.9% 
and 78.6%, respectively). In the base case, patients’ GAD was 
assumed to improve spontaneously for the first 3 years of the 
model [13], resulting in a decrease in the proportion who have 
moderate and severe GAD, and an increase in no or mild GAD. 
After 3 years the proportions remained constant in the living 
population. The proportion in each anxiety state after treatment 
is shown in Supplementary File 4, Table S4.1 (see ESM).
The reduction in GAD-7 scores after receiving treatment, 
for the seven comparators, is shown in Fig. 3. The initial 
reduction in GAD-7 reflects outcomes, as determined by the 
meta-analysis by Saramago Goncalves et al. [9]. The effect 
of each comparator was assumed to remain constant indefi-
nitely and, after 1 year, GAD-7 scores further decreased as 
patients’ symptoms continued to improve at the same rate as 
without treatment. However, the GAD-7 reduction decreased 
as, following treatment, there were fewer patients who could 
recover spontaneously, compared with no treatment.
3.2  Costs and Outcomes of DIs Compared 
with Alternatives
Table 2 shows the costs and outcomes associated with each 
of the seven comparators. The QALY and LY gains reflect 
the results from the meta-analysis [9]: on average, SSRIs 
were associated with lower anxiety scores post-treatment, 
followed by face-to-face group therapy, then by SDIs, and 
then UDIs. Both SDIs and UDIs were associated with lower 
GAD-7 scores post-treatment compared with SDCs and 
UDCs, and with no treatment. Differences between com-
parators were small and uncertain, reflected in wide and 
overlapping confidence intervals.
Differences in health care costs largely followed the 
reverse order of QALY gains—health care costs were the 
lowest for patients taking medication, and the highest in 
patients who received usual care. This is because increasing 
GAD severity is associated with an increase in health care 
costs (see Table 1). Health care costs were highly uncertain 
with overlapping confidence intervals.
SDIs and face-to-face group therapy were associated with 
the same intervention costs, as they include the same level 
of human resources. Treatment with SSRIs was more expen-
sive, as it requires contact with health care professionals 
for 5 years, for the duration of treatment. The total costs of 
different comparators follow the same order as health care 
costs, except SDIs, which incur higher total costs than UDIs 
due to the higher intervention cost.
Table 2 shows the incremental costs and effects, and the 
NMB of all seven comparators, while Fig. 4 shows the cost-
effectiveness acceptability curves (CEACs) for each com-
parator for different opportunity costs. Net benefit and the 
probability of cost effectiveness in Table 2 are shown for 
two opportunity costs: £0/QALY representing a decision 
Fig. 2  Movement through 
health states for the initial 5 
years without treatment
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maker who will only implement cost-saving interventions, 
and £15,000/QALY close to the empirical estimate of the 
opportunity cost in England [34]. The results at opportunity 
costs > £15,000/QALY are not shown as they did not change 
significantly (see Fig. 4).
SSRIs resulted in a dominant ICER and highest NMB 
at all opportunity costs, followed by group therapy, as both 
led to lower total costs and greater QALY gains than DIs. 
Usual care had the lowest NMB. Digital interventions (UDIs 
and SDIs) had a higher NMB than digital controls (UDC 
and SDC). SDIs had greater QALY gains but also higher 
costs than UDIs, so their NMB depended on the opportunity 
cost of the health system. When the opportunity cost is £0/
QALY, UDIs are ranked above SDIs, while the opposite is 
the case when opportunity cost increases to £15,000/QALY.
Results are uncertain, reflected in the wide confidence 
intervals associated with NMB, and the probability of each 
intervention being the most cost effective in Table 2. For 
example, while SSRIs have the highest NMB, there is a 
high probability it is not the most cost-effective comparator 
(0.949 probability of not being cost effective at £0/QALY 
opportunity cost, and 0.431 at £15,000/QALY).
Accumulated costs and outcomes over time are shown in 
Supplementary File 8 (see ESM). The longer the analysis 
time horizon the greater the differences in the QALY gain, 
as the benefits accrue over time. Differences in health care 
cost are driven by the clinical effectiveness of interventions, 
and so, as for QALY gains, the longer the time horizon the 
greater the cost differences. Treatment with SSRIs is the 
most expensive in the short term, but as health care cost 
savings accrue, and treatment cost reduces after 5 years, the 
total cost for SSRIs increases at a lower rate than for other 
comparators, eventually becoming the cheapest treatment 
option, after face-to-face group therapy.
3.3  Value of Information (VoI) Analysis
In the base case, the  EVPIp was £16.2 billion, indicating 
high uncertainty in the model.  EVPIp at a range of opportu-
nity costs is shown in supplementary file 9 (see ESM), with 
the lowest value of £11.4 billion when opportunity cost is 
£4000/QALY.  EVPPIP analysis suggested that uncertainty 
in the treatment effect had the greatest impact on the model 
results; the estimated VoI about the treatment effect was 
£12.9 billion.
3.4  Scenario Analyses
Scenario analyses were performed to explore the sensitivity 
of the findings to assumptions made regarding the GAD tra-
jectory, health care costs and interventions costs. The results 
were not sensitive to any of the alternative scenarios—the 
order of cost effectiveness did not change, only the magni-
tude of the difference. SSRIs dominate all other compara-
tors, while SDIs are more effective and costlier than UDIs 
(see supplementary file 10 in the ESM for details). Since 
DIs were associated with higher health care costs than group 
therapy and SSRIs, exploring the effect of increasing their 
cost even further was unnecessary.
Fig. 3  Change in mean GAD-7 
score for the initial 5-year 
period after starting treatment
 
UC=Usual care; UDC=Unsupported Digital Control; SDC=Supported Digital Control; UDI=Unsupported 
Digital Intervention; SDI=Supported Digital Intervention; GT = group therapy; SSRIs=Selective Serotonin 
Reuptake Inhibitors. 
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4  Discussion
Interest in the use of DIs for the treatment of mental health 
disorders is growing, but it is not clear whether they rep-
resent value for money in the treatment of GAD, the most 
highly prevalent mental health problem. This study used a 
decision analytic model to evaluate the cost effectiveness 
of DIs, across different types of technology and therapeutic 
modalities, from the perspective of the UK health care sys-
tem, compared with group therapy, SSRIs, non-therapeutic 
controls and usual care.
4.1  Key Findings
The expected net benefit was the highest for SSRIs followed 
by group therapy. All DIs and non-therapeutic controls led 
to higher net benefit than usual care. Supported DIs were 
associated with higher costs than unsupported DIs, but their 
NMB was greater when the opportunity cost was £3000/
QALY or higher.
These results are highly uncertain, with the VoI estimated 
to be > £11 billion. The VoI represents not only the value 
of further research in order to resolve model uncertainty, 
but also the scale of the QALYs loss and incurred costs, 
if the decision about whether to fund DIs, based on exist-
ing evidence, is incorrect. The  EVPPIP analysis found that 
uncertainty in the treatment effect had the greatest impact on 
the model results. The treatment effect was fundamental to 
establishing the cost effectiveness of DIs for GAD because 
the costs were driven largely by clinical outcomes (better 
GAD outcomes lead to lower total health care costs, com-
pensating for higher intervention costs). The value of further 
research to establish the effectiveness of DIs for GAD is 
therefore substantial, approximated at £12.9 billion.
Table 2  Mean total cost and effect of digital interventions (DIs) and alternatives for generalised anxiety disorder (GAD) (95% confidence inter-
val)
ICER incremental cost-effectiveness ratio, k opportunity cost, NMB net monetary benefit, PCE probability of cost effectiveness, QALY quality-
adjusted life-years, SDC supervised digital controls, SDI supervised digital interventions, SSRIs selective serotonin reuptake inhibitors, UC usual 
care, UDC unsupervised digital controls, UDI unsupervised digital interventions
SSRIs Group therapy SDI UDI SDC UDC UC




11.8 (9.7–14.1) 11.6 (9.2–14.0) 11.5 (8.9–14.1) 11.1 (9.4–12.4)
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688 (− 38,229 
to 49,867)
2543 (− 36,862 
to 51,940)
2360 (− 37,391 
to 57,798)
2868 (− 37,785 
to 63,454)
3067 (− 38,072 
to 65,451)






− 0.7 (− 3.4 to 
2.2)
− 1.0 (− 3.0 to 
0.8)
− 1.2 (− 3.6 to 
1.8)
− 1.4 (− 3.8 to 
1.4)
− 1.4 (− 4.5 to 
1.8)
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k = £0/QALY
 NMB (£) − 11,754 (− 
47,063 to − 
1839)
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218)
− 14,298 (− 
63,232 to − 
218)
− 14,114 (− 
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− 25)
− 14,623 (− 
74,315 to 
− 31)






 PCE 0.051 0.107 0.107 0.151 0.159 0.165 0.238
k = £15,000/
QALY





















 PCE 0.431 0.070 0.070 0.092 0.066 0.091 0.015
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4.2  Comparison with the Existing Literature
Previous studies evaluated the cost effectiveness of one 
specific DI for GAD using a single source for clinical data. 
Kumar et al. [5] evaluated the cost effectiveness of an SDI 
(mobile self-directed cognitive behaviour therapy—CBT) 
against individual CBT and usual care, and found the SDI 
to be cost saving against both comparators; however, the 
study used non-comparative data where the effect of mobile 
CBT was measured in a single-arm pilot study, while the 
effect of individual CBT was derived from a meta-analy-
sis. Furthermore, the authors did not explore probabilistic 
uncertainty in the cost-effectiveness analysis. Dear et al. [6] 
evaluated the cost effectiveness of an SDI (internet-based 
self-directed CBT) compared with usual care, using out-
comes from an RCT. The authors found that the SDI was 
more effective, but also costlier than usual care, with a high 
probability of being cost effective when the opportunity 
cost was AUS$40,000/QALY (~ £20,000/QALY at current 
exchange rate). Broadly, our analysis supports the findings 
by Kumar et al. [5] and by Dear et al. [6] that SDIs may be 
cost effective compared with usual care, albeit with great 
uncertainty. No clinical studies included head-to-head com-
parisons between DIs and individual CBT for GAD popu-
lations (only group CBT), so we could not comment on 
the finding by Kumar et al. [5] that DIs are cost effective 
compared with individual CBT.
4.3  Limitations
Estimates of clinical effectiveness used in the model were 
informed by pooled evidence for different but comparable 
interventions according to the taxonomy developed by Sara-
mago Goncalves et al. [9]. It is possible that the taxonomy 
did not account for all differences between digital interven-
tions, leading to further uncertainty in effectiveness esti-
mates. However, Saramago Goncalves et al. [9] found that 
further granulation of intervention characteristics, to account 
for additional factors such as contact time, led to inconsist-
ent effectiveness results with greater uncertainty, suggesting 
that there is no evidence that accounting for these additional 
characteristics could provide a better intervention taxonomy 
and reduce uncertainty in the findings. Furthermore, a simi-
lar approach to estimating the effectiveness of DIs has been 
taken in previous studies on depression [39, 40].
Limitations in data availability led to several assumptions 
regarding model parameters. Utilities and excess mortality in 
different severity states were informed by studies that used 
measures other than GAD-7, specifically HAM-A [12] and 
PHQ-4 [23]. HAM-A has been found to be highly correlated 
with GAD-7 [16], while correlation between PHQ-4 and 
GAD-7 is unclear. The cost of health care for different levels 
of GAD severity was based on research from 2005 (adjusted 
for inflation) [18] and on non-UK health care resource use in 
the scenario analyses [5, 35]. All three studies led to similar 
conclusions in terms of ranking and uncertainty in the cost 
Fig. 4  Cost-effectiveness 
acceptability curves (CEACs) 
for each intervention and 
control
UC=Usual care; UDC=Unsupported Digital Control; SDC=Supported Digital Control; UDI=Unsupported 
Digital Intervention; SDI=Supported Digital Intervention; GT = group therapy; SSRIs=Selective Serotonin 
Reuptake Inhibitors.
 D. Jankovic et al.
effectiveness of DIs and their alternatives. The trajectory 
of the treatment effect of different comparators is unclear. 
In our analysis we tested extreme scenarios, where the 
treatment effect lasts indefinitely (base case), and where it 
diminishes immediately after stopping treatment (scenarios 
3 and 6 in supplementary file 5, see ESM) and found that 
the assumptions did not impact the conclusions of the cost-
effectiveness analysis. When calculating costs, the duration 
of treatment with SSRIs was conservatively assumed to be 
5 years. In practice, treatment is likely to last < 5 years, 
reducing the intervention cost. The lower intervention cost 
would not change the conclusion of the analysis, where total 
cost with SSRIs is already expected to be lower than with 
other comparators.
4.4  Policy Implications and Further Research
This study found that there is considerable uncertainty 
around the cost effectiveness of DIs for GAD, and that exist-
ing evidence is not sufficient to make an informed decision 
about whether these interventions represent good value for 
money.
However, the study helps identify key topics for further 
research, namely primary data collection (e.g. RCTs) to 
establish the clinical effectiveness of digital interventions 
in the GAD population. Firstly, the study found that clini-
cal effectiveness was the key driver of cost effectiveness, 
as apparent cost savings associated with digital interven-
tions (compared with face-to-face group therapy and SSRIs) 
can be offset by higher downstream health care costs due 
to reduced effectiveness, even if that reduction is small 
and statistically non-significant. Secondly, the uncertainty 
in the clinical effect was highlighted as the key driver of 
uncertainty in the cost-effectiveness model both by the VoI 
analysis in section 3.3 and by the results of the scenario 
analyses in supplementary file 10 (see ESM), where none of 
the scenarios had a significant impact on the model findings 
because the short-term effectiveness of the comparators was 
the key determinant of the cost effectiveness.
Primary data collection would also enable the analysis of 
how to best deliver digital interventions to GAD patients. 
Specifically, we identify four factors that could impact the 
cost effectiveness that were not explored in our analysis due 
to data sparsity.
a. Optimum design of digital interventions. Our study 
categorised digital interventions based on whether they 
included support and whether they included an active 
intervention. The categorisation was based on best avail-
able evidence at the time of the study. Further studies 
evaluating a variety of digital interventions in this popu-
lation could inform how other factors, such as content 
and delivery mode, impact the effectiveness of digital 
interventions.
b. Heterogeneity in patient response. It is possible that 
digital interventions are more effective in some patient 
populations. Understanding patient characteristics that 
drive the effectiveness of digital interventions could 
allow more targeted treatment delivery.
c. Treatment sequencing. Our model compared the lifetime 
effect of single treatments for GAD, whereas in prac-
tice, patients can receive multiple cycles of the same 
therapy or a combination of therapies concurrently or 
in sequence. We did not model the cost effectiveness of 
sequential or combined treatments due to lack of data on 
effectiveness. As such, we do not know whether DIs may 
be cost effective as a first-line treatment in a stepped 
care model before medication and individual or group 
therapy is offered to those who do not respond to DIs.
d. Role of DIs in increasing capacity of the health sys-
tem. The analysis does not consider the capacity of 
the health system to deliver treatment for GAD. Digi-
tal interventions may be used to improve capacity in 
health systems where there are significant waitlists for 
face-to-face treatment—a challenge likely to grow as 
result of increased incidence of mental health issues 
and decreased capacity for delivering face-to-face care 
associated with the COVID-19 pandemic. The health 
consequences of being able to offer treatment to a larger 
number of GAD patients, or reducing delay to treatment, 
may be substantial and may justify a lower effectiveness 
of DIs, as demonstrated in a recent study on depression 
[40].
5  Conclusions
This study is the first to collate all available clinical evi-
dence to evaluate the cost effectiveness of DIs for GAD, 
irrespective of the type of DI used, and in comparison with 
multiple alternative care options. On average, DIs were 
associated with lower NMB compared with SSRIs and with 
face-to-face group therapy, but greater NMB compared with 
non-therapeutic controls and with usual care. Although sup-
ported DIs had a higher human resource cost than unsup-
ported DIs, they led to greater NMB when opportunity cost 
was £3000/QALY or greater. The high uncertainty of the 
results prevents any firm conclusions about the cost effec-
tiveness of DIs. However, the analysis highlights key areas 
for further research: primary data collection to establish the 
effectiveness and the optimum role of digital interventions 
in the treatment of GAD.
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